Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Pediatric Pulmonology|August 11, 2011
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosisNicole Mayer-Hamblett, Richard A Kronmal, Ronald L Gibson, et al.
BMC Microbiology|October 27, 2023
Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infectionBrandie D Wagner, Edith T Zemanick, Scott D Sagel, et al.
Pediatric Pulmonology|February 11, 2005
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosisRobin Deterding, George Retsch-Bogart, Laura Milgram, et al.
American Journal of Respiratory and Critical Care Medicine|December 13, 2016
Progression of Lung Disease in Preschool Patients with Cystic FibrosisSanja Stanojevic, Stephanie D Davis, George Retsch-Bogart, et al.
Pediatric Pulmonology|July 3, 2013
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosisNicole Mayer-Hamblett, Margaret Rosenfeld, Miriam M Treggiari, et al.
Pediatric Pulmonology|December 2, 2004
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung diseaseRichard B Moss, Nicole Mayer-Hamblett, Jeffrey Wagener, et al.
American Journal of Respiratory and Critical Care Medicine|June 12, 2018
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized TrialNicole Mayer-Hamblett, George Retsch-Bogart, Margaret Kloster, et al.
Pediatric Pulmonology|July 3, 2010
Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohortMargaret Rosenfeld, Julia Emerson, Sharon McNamara, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical TrialClaire Wainwright, Susanna A McColley, Paul McNally, et al.
Pediatric Pulmonology|May 31, 2007
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosisRonald L Gibson, Julia Emerson, Nicole Mayer-Hamblett, et al.
Pageof 4